[Skip to Content]

FAQs

Who retains the rights to any intellectual property generated by a proposal?

Management of intellectual property will be determined by the proposal applicant’s institutional policies, with “walk-in” and “use” terms consistent with the SBIR program.

Should I disclose any unprotected proprietary information in the submission?

Protecting proprietary information is the responsibility of the applicant and the applicant institution. Consistent with NIH policy, applicants are discouraged from submitting information considered proprietary unless it is deemed essential for proper evaluation of the application. However, when the application contains information that constitutes trade secrets, or information that is commercial or financial, or information that is confidential or privileged, identify the pages in the application that contain this information by marking those paragraphs or lines with an asterisk (*) at the beginning of the paragraph. Indicate at the beginning of the Research Plan which pages contain asterisks and a note stating: "The following sections marked with an asterisk contain proprietary/privileged information that [name of applicant] requests not be released to persons outside the Government, except for purposes of review and evaluation." When information in the application constitutes trade secrets or information that is commercial or financial, or information that is confidential or privileged, it is furnished to the Government in confidence with the understanding that the information shall be used or disclosed only for evaluation of this application. If a grant is awarded as a result of or in connection with the submission of this application, the Government shall have the right to use or disclose the information to the extent authorized by law.

Who can apply for this grant call?

In order to be eligible, applicants must be employed by a US-based small business operating in the U.S. as defined under the SBIR program (less than 500 employees and qualifying as a small business concern under 13CFR Part 121). There may be sub-awards to universities, but the primary recipient will be the company.

Are international companies outside of the United States eligible to participate?

Companies that are based outside of the US are not eligible to apply. Non-US companies can be paid fees for service to a US-based company, but not fees for research activities.

When are applications due? 

Expressions of Interest are due by 11:59pm EST April 12, 2018.

Full proposals are due by 11:59pm EST June 12, 2018.

How much funding is available?

Applicants may request up to $50,000 per Validation Award for an expected duration of 3 to 6 months of work and up to $250,000 per Accelerator Award for an expected duration of up to one year of work.

Where do I submit my Expression of Interest (pre-proposal)?

All Expressions of Interest must be submitted through the online submission system.

When will I be notified if my Expression of Interest has been selected to submit a full proposal?

All applicants who submit an Expression of Interest will be notified on or before April 26, 2018 as to whether or not they have been selected to advance to the full proposal phase.

I have been invited to submit a full proposal. Now what?

You will receive detailed instructions and information with the invitation to submit a full proposal.

If you are invited to submit a full proposal, it must be submitted through the online submission system no later than 11:59pm EST June 12, 2018. No material can be submitted directly to TRISH or CIMIT staff.

Follow the step-by-step instructions on the web-based submission site. The files do not need to be loaded all at once. The PI may log on as many times as he or she wishes until the deadline.

Who reviews the applications?

The review panels are made up of practicing clinical specialists, engineers and scientists with broad experience in medical innovation and space health. Full proposal applicants can suggest reviewers, though no assurance is given that suggested reviewers will be utilized. Applicants can also provide names of potential reviewers who they would prefer not be used, and every effort will be made to accommodate these requests. These requests should be included in a letter uploaded with the other supporting documents.

Is there anything "special" that applicants should know?

Key elements of a strong application are experienced investigators, a history of strong collaboration, innovation, and commercialization potential.

Proposal teams should be aware of the unique environmental factors of spaceflight, and particularly deep space away from Earth and the Van Allen belts. This includes microgravity, substantially elevated cosmic and solar radiation, acoustic and electromagnetic noise from the spacecraft, limits on mass/power/volume/crew-training time, etc. The article "From the bench to exploration medicine: NASA life sciences translational research for human exploration and habitation missions" is a helpful reference.

What "types" of proposals are of interest?

TRISH is looking for disruptive science and technology, not incremental advances. Hence, TRISH is unlikely to fund any approaches that are incremental, or approaches that have been funded previously by NASA.

Who should I list as collaborators?

List only individuals who are considered key personnel or significant contributors to the work that will be performed, and who have agreed to their role.

I am writing an Expression of Interest. May I include several references?

You can include as many references as you would like, but they must be included in the two-page limit.

Should I submit copies of relevant publications?

Please do not submit copies of relevant publications. Standard citation of publications is acceptable.

Will you accept a video showing how my system works?

Videos are not accepted.

Are there any budget restrictions or limitations?

All funds are intended to be used for steering the product towards spaceflight applications while in parallel moving the product along the commercialization path. Funds can be spent on technical work, clinical proof of concept, etc., but not for “business activities” (e.g. a “market study”, patent prosecution, FDA documentation, etc.). Capital and non-capital equipment must be well justified to the purpose and exclusive need of the project. Alterations and renovations will not be supported.

Are indirect costs provided?

The award amounts are total costs. Budgets should include direct and indirect costs.  If you are using an indirect cost rate, it must be a federally negotiated rate. 

When would I receive my funding?

The timeliness of your revisions to the administrative materials and obtaining any necessary protocol approvals will affect when you receive your award. We plan to provide funding no later than September 30, 2018. However, if your work involves human subjects, data or tissue derived, or live animals, the necessary IRB and IACUC approvals must be received prior to the activation of your award.

What are my reporting responsibilities if I receive an award?

The PI shall provide a final written report to TRISH. Interim progress reports may be requested by CIMIT.

What are the reporting requirements?

The reporting requirements vary by award type and are as follows:

  1. Validation Award reporting requirements: The PI shall submit a Quarterly Technical Progress Report within 15 calendar days at the end of each quarter, followed by a Final Technical Report. The Final Technical Report shall be submitted within 60 calendar days of the award performance end date. Final payment is contingent upon receipt and approval of the Final Report.
  2. Accelerator Award reporting requirements: The PI shall submit an Annual Technical Progress Report within 15 calendar days of the anniversary of the award, followed by a Final Technical Report. The Final Technical Report shall be submitted within 60 calendar days of the award performance end date. Final payment is contingent upon receipt and approval of the Final Report.

Is early stage research supported?

Applications to support early stage research are not encouraged.

Share